Product Description
Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03059615)
Mechanisms of Action: IL1 Modulator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Immune System Key
Company Location: Eastern America
Company Founding Year: 2018
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Myelodysplastic Syndrome|Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05661201 |
STUDY00005711 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2027-01-01 |
50% |
2026-03-07 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT04365179 |
NCT04365179 | P1 |
Recruiting |
Myelodysplastic Syndrome |
2025-06-30 |
2024-07-11 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|